The DOI matches its Crossref record; 80 of the 80 references it cites were found in a registry or an index.
NRF2 addiction in cancer cells
Open accessAbstract
The Kelch‐like ECH‐associated protein 1/nuclear factor erythroid‐derived 2‐like 2 (KEAP 1‐NRF 2) system is a pivotal defense mechanism against oxidative and electrophilic stress. Although transient NRF 2 activation in response to stress is beneficial for health, persistent NRF 2 activation in cancer cells has deleterious effects on cancer‐bearing hosts by conferring therapeutic resistance and aggressive tumorigenic activity on cancer cells. Because NRF 2 increases the antioxidant and detoxification capability of cancer cells, persistently high levels of NRF 2 activity enhance therapeutic resistance of cancer cells. NRF 2 also drives metabolic reprogramming to establish cellular metabolic processes that are advantageous for cell proliferation in cooperation with other oncogenic pathways. As a result of these advantages, cancer cells with persistent activation of NRF 2 often develop “NRF 2 addiction” and show malignant phenotypes leading to poor prognoses in cancer patients. Inhibition of NRF 2 is a promising therapeutic approach for NRF 2‐addicted cancers and NRF 2 inhibitors are being actively developed. However, giving systemic NRF 2 inhibitors might have undesirable effects on cancer‐bearing hosts, considering the central roles of NRF 2 in cytoprotection. To avoid these side‐effects, new therapeutic targets besides NRF 2 for NRF 2‐addicted cancers have been actively explored. This review introduces recent studies describing the development and characterization of NRF 2‐addicted cancers, as well as their potential therapeutic targets. Expected advances in diagnostic and therapeutic interventions for NRF 2‐addicted cancers are also discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mutational landscape and significance across 12 major cancer types
Kandoth, C., McLellan, M. D., Vandin, F., Ye, K., Niu, B., Lu, C., Xie, M., Zhang, Q., McMichael, J. F., Wyczalkowski, M. A., et al. (2013) · Nature · doi:10.1038/nature12634 · Cited by 4,419
Komatsu, M., Kurokawa, H., Waguri, S., Taguchi, K., Kobayashi, A., Ichimura, Y., Sou, Y.-S., Ueno, I., Sakamoto, A., Tong, K. I., et al. (2010) · Nature Cell Biology · doi:10.1038/ncb2021 · Cited by 2,288
Self-citationOncogene-induced Nrf2 transcription promotes ROS detoxification and tumorigenesis
DeNicola, G. M., Karreth, F. A., Humpton, T. J., Gopinathan, A., Wei, C., Frese, K., Mangal, D., Yu, K. H., Yeo, C. J., Calhoun, E. S., et al. (2011) · Nature · doi:10.1038/nature10189 · Cited by 2,277
Nrf2 suppresses macrophage inflammatory response by blocking proinflammatory cytokine transcription
Kobayashi, E. H., Suzuki, T., Funayama, R., Nagashima, T., Hayashi, M., Sekine, H., Tanaka, N., Moriguchi, T., Motohashi, H., Nakayama, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms11624 · Cited by 1,878 · cited 1×
“Further, NRF2 possesses potent anti-inflammatory activity and alleviates a variety of inflammatory conditions, including autoimmune diseases.(8,9) In line with these protective roles of the KEAP1-NRF2 system, NRF2 activation effectively prevents chemical carcinogenesis by increasing antioxidant and detoxification capa…”
BackgroundSelf-citationNrf2–Keap1 defines a physiologically important stress response mechanism
Motohashi, H., & Yamamoto, M. (2004) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2004.09.003 · Cited by 1,725 · cited 2×
“NRF2 then translocates to the nucleus and induces a battery of cytoprotective genes by binding to the antioxidant response element (ARE) by heterodimerization with small MAF proteins (Figure 1, “Transient NRF2 activation”).(1) Biochemical, biophysical and structural analyses showed that KEAP1 forms a cherry bob-like h…”
BackgroundSelf-citationNrf2 Redirects Glucose and Glutamine into Anabolic Pathways in Metabolic Reprogramming
Mitsuishi, Y., Taguchi, K., Kawatani, Y., Shibata, T., Nukiwa, T., Aburatani, H., Yamamoto, M., & Motohashi, H. (2012) · Cancer Cell · doi:10.1016/j.ccr.2012.05.016 · Cited by 1,395 · cited 3×
“, metabolic genes in addition to cytoprotective genes).(63) NRF2 activates genes encoding enzymes for NADPH production and the pentose phosphate pathway, and subsequently facilitates the metabolic flux of glucose into purine nucleotide synthesis and that of glutamine into glutaminolysis and glutathione synthesis.”
BackgroundSelf-citationPhosphorylation of p62 Activates the Keap1-Nrf2 Pathway during Selective Autophagy
Ichimura, Y., Waguri, S., Sou, Y.-S., Kageyama, S., Hasegawa, J., Ishimura, R., Saito, T., Yang, Y., Kouno, T., Fukutomi, T., et al. (2013) · Molecular Cell · doi:10.1016/j.molcel.2013.08.003 · Cited by 1,205
Self-citationRamos-Gomez, M., Kwak, M.-K., Dolan, P. M., Itoh, K., Yamamoto, M., Talalay, P., & Kensler, T. W. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.051618798 · Cited by 1,102
Keap1-null mutation leads to postnatal lethality due to constitutive Nrf2 activation
Wakabayashi, N., Itoh, K., Wakabayashi, J., Motohashi, H., Noda, S., Takahashi, S., Imakado, S., Kotsuji, T., Otsuka, F., Roop, D. R., et al. (2003) · Nature Genetics · doi:10.1038/ng1248 · Cited by 883
Self-citationTong, K. I., Katoh, Y., Kusunoki, H., Itoh, K., Tanaka, T., & Yamamoto, M. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.8.2887-2900.2006 · Cited by 759
Rada, P., Rojo, A. I., Chowdhry, S., McMahon, M., Hayes, J. D., & Cuadrado, A. (2011) · Molecular and Cellular Biology · doi:10.1128/mcb.01204-10 · Cited by 759 · cited 2×
“Whereas NRF2 is trapped by the CUL3-KEAP1 complex in the cytoplasm and ubiquitinated for degradation, NRF2 is also ubiquitinated by the CUL1-bTrCP complex after being phosphorylated by GSK3.(77,78) As GSK3 is phosphorylated by AKT and inactivated, CUL1-bTrCP complex-mediated degradation of NRF2 is inhibited in prolife…”
BackgroundNRF2 regulates serine biosynthesis in non–small cell lung cancer
DeNicola, G. M., Chen, P.-H., Mullarky, E., Sudderth, J. A., Hu, Z., Wu, D., Tang, H., Xie, Y., Asara, J. M., Huffman, K. E., et al. (2015) · Nature Genetics · doi:10.1038/ng.3421 · Cited by 746
Structural basis for defects of Keap1 activity provoked by its point mutations in lung cancer
Padmanabhan, B., Tong, K. I., Ohta, T., Nakamura, Y., Scharlock, M., Ohtsuji, M., Kang, M.-I., Kobayashi, A., Yokoyama, S., & Yamamoto, M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.01.013 · Cited by 735 · cited 7×
“Phosphorylated p62 has a higher affinity for KEAP1 than the non-phosphorylated form of p62, and competes with NRF2 for KEAP1 binding.51 Aberrant accumula- tion of p62 is frequently observed in hepatocellular carcinoma, and causes persistent activation of NRF2.”
MethodInfluentialMaj, T., Wang, W., Crespo, J., Zhang, H., Wang, W., Wei, S., Zhao, L., Vatan, L., Shao, I., Szeliga, W., et al. (2017) · Nature Immunology · doi:10.1038/ni.3868 · Cited by 733
Shibata, T., Ohta, T., Tong, K. I., Kokubu, A., Odogawa, R., Tsuta, K., Asamura, H., Yamamoto, M., & Hirohashi, S. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0806268105 · Cited by 728
Enomoto, A. (2001) · Toxicological Sciences · doi:10.1093/toxsci/59.1.169 · Cited by 728
Nrf2-Keap1 pathway promotes cell proliferation and diminishes ferroptosis
Fan, Z., Wirth, A.-K., Chen, D., Wruck, C. J., Rauh, M., Buchfelder, M., & Savaskan, N. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.65 · Cited by 692
Chowdhry, S., Zhang, Y., McMahon, M., Sutherland, C., Cuadrado, A., & Hayes, J. D. (2013) · Oncogene · doi:10.1038/onc.2012.388 · Cited by 657
Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis
Romero, R., Sayin, V. I., Davidson, S. M., Bauer, M. R., Singh, S. X., LeBoeuf, S. E., Karakousi, T. R., Ellis, D. C., Bhutkar, A., Sánchez-Rivera, F. J., et al. (2017) · Nature Medicine · doi:10.1038/nm.4407 · Cited by 652
Persistent activation of Nrf2 through p62 in hepatocellular carcinoma cells
Inami, Y., Waguri, S., Sakamoto, A., Kouno, T., Nakada, K., Hino, O., Watanabe, S., Ando, J., Iwadate, M., Yamamoto, M., et al. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201102031 · Cited by 604
Adam, J., Hatipoglu, E., O'Flaherty, L., Ternette, N., Sahgal, N., Lockstone, H., Baban, D., Nye, E., Stamp, G. W., Wolhuter, K., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.09.006 · Cited by 585 · cited 1×
“Type II papillary renal cell carcinoma, which is accompanied by FH mutations, shows elevated expression of NRF2 target genes and highly malignant phenotypes.(54,55) 3.”
BackgroundTGF-β Promotes Heterogeneity and Drug Resistance in Squamous Cell Carcinoma
Oshimori, N., Oristian, D., & Fuchs, E. (2015) · Cell · doi:10.1016/j.cell.2015.01.043 · Cited by 471
Arbour, K. C., Jordan, E., Kim, H. R., Dienstag, J., Yu, H. A., Sanchez-Vega, F., Lito, P., Berger, M., Solit, D. B., Hellmann, M., et al. (2018) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-17-1841 · Cited by 466
Tong, K. I., Padmanabhan, B., Kobayashi, A., Shang, C., Hirotsu, Y., Yokoyama, S., & Yamamoto, M. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00753-07 · Cited by 442
Solis, L. M., Behrens, C., Dong, W., Suraokar, M., Ozburn, N. C., Moran, C. A., Corvalan, A. H., Biswal, S., Swisher, S. G., Bekele, B. N., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-3352 · Cited by 428
Ooi, A., Wong, J.-C., Petillo, D., Roossien, D., Perrier-Trudova, V., Whitten, D., Min, B. W. H., Tan, M.-H., Zhang, Z., Yang, X. J., et al. (2011) · Cancer Cell · doi:10.1016/j.ccr.2011.08.024 · Cited by 401 · cited 1×
“Type II papillary renal cell carcinoma, which is accompanied by FH mutations, shows elevated expression of NRF2 target genes and highly malignant phenotypes.(54,55) 3.”
BackgroundOkawa, H., Motohashi, H., Kobayashi, A., Aburatani, H., Kensler, T. W., & Yamamoto, M. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.10.185 · Cited by 387
Self-citationNRF2 Promotes Tumor Maintenance by Modulating mRNA Translation in Pancreatic Cancer
Chio, I. I. C., Jafarnejad, S. M., Ponz-Sarvise, M., Park, Y., Rivera, K., Palm, W., Wilson, J., Sangar, V., Hao, Y., Öhlund, D., et al. (2016) · Cell · doi:10.1016/j.cell.2016.06.056 · Cited by 378
Zhang, P., Singh, A., Yegnasubramanian, S., Esopi, D., Kombairaju, P., Bodas, M., Wu, H., Bova, S. G., & Biswal, S. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0589 · Cited by 374
Iida, K., Itoh, K., Kumagai, Y., Oyasu, R., Hattori, K., Kawai, K., Shimazui, T., Akaza, H., & Yamamoto, M. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1906 · Cited by 370
Jeong, Y., Hoang, N. T., Lovejoy, A., Stehr, H., Newman, A. M., Gentles, A. J., Kong, W., Truong, D., Martin, S., Chaudhuri, A., et al. (2017) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0127 · Cited by 345
Oncogenic KRAS Confers Chemoresistance by Upregulating NRF2
Tao, S., Wang, S., Moghaddam, S. J., Ooi, A., Chapman, E., Wong, P. K., & Zhang, D. D. (2014) · Cancer Research · doi:10.1158/0008-5472.can-14-1439 · Cited by 291
Keap1 Mutations and Nrf2 Pathway Activation in Epithelial Ovarian Cancer
Konstantinopoulos, P. A., Spentzos, D., Fountzilas, E., Francoeur, N., Sanisetty, S., Grammatikos, A. P., Hecht, J. L., & Cannistra, S. A. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4668 · Cited by 270
Fukutomi, T., Takagi, K., Mizushima, T., Ohuchi, N., & Yamamoto, M. (2014) · Molecular and Cellular Biology · doi:10.1128/mcb.01191-13 · Cited by 260
Satoh, H., Moriguchi, T., Takai, J., Ebina, M., & Yamamoto, M. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-4499 · Cited by 251
Glutathione biosynthesis is a metabolic vulnerability in PI(3)K/Akt-driven breast cancer
Lien, E. C., Lyssiotis, C. A., Juvekar, A., Hu, H., Asara, J. M., Cantley, L. C., & Toker, A. (2016) · Nature Cell Biology · doi:10.1038/ncb3341 · Cited by 249
Ogura, T., Tong, K. I., Mio, K., Maruyama, Y., Kurokawa, H., Sato, C., & Yamamoto, M. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0914036107 · Cited by 229
Genetic Analysis of Cytoprotective Functions Supported by Graded Expression of Keap1
Taguchi, K., Maher, J. M., Suzuki, T., Kawatani, Y., Motohashi, H., & Yamamoto, M. (2010) · Molecular and Cellular Biology · doi:10.1128/mcb.01591-09 · Cited by 225
Self-citationShibata, T., Kokubu, A., Saito, S., Narisawa-Saito, M., Sasaki, H., Aoyagi, K., Yoshimatsu, Y., Tachimori, Y., Kushima, R., Kiyono, T., et al. (2011) · Neoplasia · doi:10.1593/neo.11750 · Cited by 224
Accumulation of p62/SQSTM 1 is associated with poor prognosis in patients with lung adenocarcinoma
Inoue, D., Suzuki, T., Mitsuishi, Y., Miki, Y., Suzuki, S., Sugawara, S., Watanabe, M., Sakurada, A., Endo, C., Uruno, A., et al. (2012) · Cancer Science · doi:10.1111/j.1349-7006.2012.02216.x · Cited by 204
Self-citationRecurrent Loss of NFE2L2 Exon 2 Is a Mechanism for Nrf2 Pathway Activation in Human Cancers
Goldstein, L. D., Lee, J., Gnad, F., Klijn, C., Schaub, A., Reeder, J., Daemen, A., Bakalarski, C. E., Holcomb, T., Shames, D. S., et al. (2016) · Cell Reports · doi:10.1016/j.celrep.2016.08.010 · Cited by 200
Nrf2-deficiency creates a responsive microenvironment for metastasis to the lung
Satoh, H., Moriguchi, T., Taguchi, K., Takai, J., Maher, J. M., Suzuki, T., Winnard, P. T., Raman, V., Ebina, M., Nukiwa, T., et al. (2010) · Carcinogenesis · doi:10.1093/carcin/bgq105 · Cited by 197
Ge, W., Zhao, K., Wang, X., Li, H., Yu, M., He, M., Xue, X., Zhu, Y., Zhang, C., Cheng, Y., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.09.008 · Cited by 188
Zhang, M., Zhang, C., Zhang, L., Yang, Q., Zhou, S., Wen, Q., & Wang, J. (2015) · BMC Cancer · doi:10.1186/s12885-015-1541-1 · Cited by 179
Halofuginone enhances the chemo-sensitivity of cancer cells by suppressing NRF2 accumulation
Tsuchida, K., Tsujita, T., Hayashi, M., Ojima, A., Keleku-Lukwete, N., Katsuoka, F., Otsuki, A., Kikuchi, H., Oshima, Y., Suzuki, M., et al. (2017) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2016.12.041 · Cited by 166
KEAP1 loss modulates sensitivity to kinase targeted therapy in lung cancer
Krall, E. B., Wang, B., Munoz, D. M., Ilic, N., Raghavan, S., Niederst, M. J., Yu, K., Ruddy, D. A., Aguirre, A. J., Kim, J. W., et al. (2017) · eLife · doi:10.7554/elife.18970 · Cited by 160
Shibata, T., Saito, S., Kokubu, A., Suzuki, T., Yamamoto, M. P., & Hirohashi, S. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0384 · Cited by 135
NRF2 and glutathione are key resistance mediators to temozolomide in glioma and melanoma cells
Rocha, C. R. R., Kajitani, G. S., Quinet, A., Fortunato, R. S., & Menck, C. F. M. (2016) · Oncotarget · doi:10.18632/oncotarget.10129 · Cited by 135
Stress-Activated NRF2-MDM2 Cascade Controls Neoplastic Progression in Pancreas
Todoric, J., Antonucci, L., Caro, G. D., Li, N., Wu, X., Lytle, N. K., Dhar, D., Banerjee, S., Fagman, J. B., Browne, C. D., et al. (2017) · Cancer Cell · doi:10.1016/j.ccell.2017.10.011 · Cited by 132
Honkura, Y., Matsuo, H., Murakami, S., Sakiyama, M., Mizutari, K., Shiotani, A., Yamamoto, M. P., Morita, I., Shinomiya, N., Kawase, T., et al. (2016) · Scientific Reports · doi:10.1038/srep19329 · Cited by 130
Self-citationRegulatory Nexus of Synthesis and Degradation Deciphers Cellular Nrf2 Expression Levels
Suzuki, T., Shibata, T., Takaya, K., Shiraishi, K., Kohno, T., Kunitoh, H., Tsuta, K., Furuta, K., Goto, K., Hosoda, F., et al. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00065-13 · Cited by 128
Self-citationNrf2 is required to maintain the self-renewal of glioma stem cells
Zhu, J., Wang, H., Sun, Q., Ji, X., Zhu, L., Cong, Z., Zhou, Y., Liu, H., & Zhou, M. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-380 · Cited by 122
Enhanced Degradation of Misfolded Proteins Promotes Tumorigenesis
Chen, L., Brewer, M. D., Guo, L., Wang, R., Jiang, P., & Yang, X. (2017) · Cell Reports · doi:10.1016/j.celrep.2017.03.010 · Cited by 113
Satoh, H., Moriguchi, T., Saigusa, D., Baird, L., Yu, L., Rokutan, H., Igarashi, K., Ebina, M., Shibata, T., & Yamamoto, M. P. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-1584 · Cited by 104
Nrf2 Enhances Cholangiocyte Expansion in Pten-Deficient Livers
Taguchi, K., Hirano, I., Itoh, T., Tanaka, M., Miyajima, A., Suzuki, A., Motohashi, H., & Yamamoto, M. P. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.01384-13 · Cited by 98
Self-citationMyeloid Lineage–Specific Deletion of Antioxidant System Enhances Tumor Metastasis
Hiramoto, K., Satoh, H., Suzuki, T., Moriguchi, T., Pi, J., Shimosegawa, T., & Yamamoto, M. P. (2014) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-14-0094 · Cited by 97
Fabrizio, F. P., Costantini, M., Copetti, M., la Torre, A., Sparaneo, A., Fontana, A., Poeta, M. L., Gallucci, M., Sentinelli, S., Graziano, P., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.14492 · Cited by 92
The Nrf2 transcription factor contributes to resistance to cisplatin in bladder cancer
Hayden, A. L., Douglas, J., Sommerlad, M., Andrews, L. P., Gould, K., Hussain, S. A., Thomas, G. J., Packham, G., & Crabb, S. J. (2014) · Urologic Oncology Seminars and Original Investigations · doi:10.1016/j.urolonc.2014.02.006 · Cited by 91
Systemic Activation of NRF2 Alleviates Lethal Autoimmune Inflammation in Scurfy Mice
Suzuki, T., Murakami, S., Biswal, S. S., Sakaguchi, S., Harigae, H., Yamamoto, M. P., & Motohashi, H. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00063-17 · Cited by 89
Self-citationNrf2 Overexpression Predicts Prognosis and 5-FU Resistance in Gastric Cancer
Hu, X., Yao, J., Gao, S., Wang, X., Peng, X.-Q., Yang, Y., & Feng, X. (2013) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2013.14.9.5231 · Cited by 82
NRF2 immunolocalization in human breast cancer patients as a prognostic factor
Onodera, Y., Motohashi, H., Takagi, K., Miki, Y., Shibahara, Y., Watanabe, M., Ishida, T., Hirakawa, H., Sasano, H., Yamamoto, M., et al. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0234 · Cited by 81
Self-citationHyperactivation of Nrf2 in early tubular development induces nephrogenic diabetes insipidus
Suzuki, T., Seki, S., Hiramoto, K., Naganuma, E., Kobayashi, E. H., Yamaoka, A., Baird, L., Takahashi, N., Sato, H., & Yamamoto, M. P. (2017) · Nature Communications · doi:10.1038/ncomms14577 · Cited by 79
Murakami, S., Suzuki, T., Harigae, H., Roméo, P., Yamamoto, M. P., & Motohashi, H. (2017) · Molecular and Cellular Biology · doi:10.1128/mcb.00086-17 · Cited by 75
Self-citationMartínez, V. D., Vucic, E. A., Thu, K. L., Pikor, L. A., Lam, S. C., & Lam, W. L. (2014) · Head & Neck · doi:10.1002/hed.23663 · Cited by 72
Ji, L., Wei, Y., Jiang, T., & Wang, S. (2014) · Europe PMC (PubMed Central) · Cited by 70
Kawasaki, Y., Okumura, H., Uchikado, Y., Kita, Y., Sasaki, K., Owaki, T., Ishigami, S., & Natsugoe, S. (2014) · Annals of Surgical Oncology · doi:10.1245/s10434-014-3600-2 · Cited by 69
Functional Role of NRF2 in Cervical Carcinogenesis
Ma, J., Hatila, T., Jiao, S.-J., Jian-He, Z., Jing-Bao, X., & Hasim, A. (2015) · PLoS ONE · doi:10.1371/journal.pone.0133876 · Cited by 65
Nuclear Nrf2 expression is related to a poor survival in pancreatic adenocarcinoma
Soini, Y., Eskelinen, M. J., Juvonen, P., Kärjä, V. J., Haapasaari, K., Saarela, A., & Karihtala, P. (2013) · Pathology - Research and Practice · doi:10.1016/j.prp.2013.10.001 · Cited by 64
Kawasaki, Y., Ishigami, S., Arigami, T., Uenosono, Y., Yanagita, S., Uchikado, Y., Kita, Y., Nishizono, Y., Okumura, H., Nakajo, A., et al. (2015) · BMC Cancer · doi:10.1186/s12885-015-1008-4 · Cited by 62
Activation of the NRF2 pathway and its impact on the prognosis of anaplastic glioma patients
Kanamori, M., Higa, T., Sonoda, Y., Murakami, S., Dodo, M., Kitamura, H., Taguchi, K., Shibata, T., Watanabe, M., Suzuki, H., et al. (2014) · Neuro-Oncology · doi:10.1093/neuonc/nou282 · Cited by 62
Self-citationHintsala, H., Jokinen, E., Haapasaari, K., Moza, M., Ristimaki, A. P., Soini, Y., Koivunen, J. P., & Karihtala, P. (2016) · PubMed · Cited by 54
IL-11 contribution to tumorigenesis in an NRF2 addiction cancer model
Kitamura, H., Onodera, Y., Murakami, S., Suzuki, T., & Motohashi, H. (2017) · Oncogene · doi:10.1038/onc.2017.236 · Cited by 54
Self-citationLiew, P., Hsu, C.-S., Liu, W.-M., Lee, Y., Lee, Y.-C., & Chen, C. (2015) · PubMed · Cited by 49
Ji, X., CHEN, S.-H., Zhu, L., Pan, H., Zhou, Y., Li, W., You, W., Gao, C.-C., Zhu, J., Jiang, K., et al. (2013) · Oncology Reports · doi:10.3892/or.2013.2476 · Cited by 47
Zhao, M., Xu, H., Zhang, B., Hong, B., Yan, W. X., & Zhang, J. (2015) · Human Pathology · doi:10.1016/j.humpath.2015.02.009 · Cited by 38
Clinical implication of Keap1 and phosphorylated Nrf2 expression in hepatocellular carcinoma
Chen, J., Yu, Y.-J., Ji, T., Ma, R., Chen, M., Li, G.-F., Li, F.-B., Ding, Q., Kang, Q., Huang, D.-Y., et al. (2016) · Cancer Medicine · doi:10.1002/cam4.788 · Cited by 34
Shirasaki, K., Taguchi, K., Unno, M., Motohashi, H., & Yamamoto, M. P. (2014) · Hepatology · doi:10.1002/hep.27020 · Cited by 33
Self-citationNrf2 Expressions Correlate with WHO Grades in Gliomas and Meningiomas
Tsai, W., Hueng, D., Lin, C.-R., Yang, T. C. ‐., & Gao, H. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms17050722 · Cited by 26
Simultaneous K-ras activation and Keap1 deletion cause atrophy of pancreatic parenchyma
Hamada, S., Shimosegawa, T., Taguchi, K., Nabeshima, T., Yamamoto, M. P., & Masamune, A. (2017) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00228.2017 · Cited by 24
Keap1 expression has independent prognostic value in pancreatic adenocarcinomas
Isohookana, J., Haapasaari, K., Soini, Y., & Karihtala, P. (2015) · Diagnostic Pathology · doi:10.1186/s13000-015-0258-4 · Cited by 23
Cited by
The pentose phosphate pathway in health and disease
TeSlaa, T., Ralser, M., Fan, J., & Rabinowitz, J. D. (2023) · Nature Metabolism · doi:10.1038/s42255-023-00863-2 · Cited by 650
NRF2 controls iron homeostasis and ferroptosis through HERC2 and VAMP8
Anandhan, A., Dodson, M., Shakya, A., Chen, J., Liu, P., Wei, Y., Tan, H., Wang, Q., Jiang, Z., Yang, K., et al. (2023) · Science Advances · doi:10.1126/sciadv.ade9585 · Cited by 519
Breakdown of an Ironclad Defense System: The Critical Role of NRF2 in Mediating Ferroptosis
Anandhan, A., Dodson, M., Schmidlin, C. J., Liu, P., & Zhang, D. D. (2020) · Cell Chemical Biology · doi:10.1016/j.chembiol.2020.03.011 · Cited by 442
Activators and inhibitors of NRF2: a review of their potential for clinical development
Robledinos-Antón, N., Fernández-Ginés, R., Manda, G., & Cuadrado, A. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/9372182 · Cited by 413
Hypoxia, oxidative stress, and the interplay of HIFs and NRF2 signaling in cancer
Bae, T., Hallis, S. P., & Kwak, M.-K. (2024) · Experimental & Molecular Medicine · doi:10.1038/s12276-024-01180-8 · Cited by 354
Metadata
- Authors
- Kitamura, H., & Motohashi, H.
- Venue
- Cancer Science
- Publisher
- Wiley
- Published
- 2018-03-10
- Volume
- 109
- Issue
- 4
- Pages
- 900-911
- ISSN
- 1347-9032 (ISSN-L)
- 1349-7006
- OpenAlex
- W2790803800
- Cited by
- 275
- References
- 80
- FWCI
- 9.42
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.